Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
43.53
+0.02 (0.06%)
Feb 9, 2026, 11:12 AM EST - Market open
Vera Therapeutics Employees
Vera Therapeutics had 224 employees as of September 30, 2025. The number of employees increased by 142 or 173.17% compared to the same quarter last year.
Employees
224
Change
142
Growth
173.17%
Revenue / Employee
n/a
Profits / Employee
-$1,124,746
Market Cap
3.09B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 224 | 142 | 173.17% |
| Jun 30, 2025 | 192 | 120 | 166.67% |
| Mar 31, 2025 | 152 | 97 | 176.36% |
| Dec 31, 2024 | 112 | 61 | 119.61% |
| Sep 30, 2024 | 82 | 33 | 67.35% |
| Jun 30, 2024 | 72 | 23 | 46.94% |
| Mar 31, 2024 | 55 | 9 | 19.57% |
| Dec 31, 2023 | 51 | 5 | 10.87% |
| Sep 30, 2023 | 49 | 8 | 19.51% |
| Jun 30, 2023 | 49 | 20 | 68.97% |
| Mar 31, 2023 | 46 | 28 | 155.56% |
| Dec 31, 2022 | 46 | 29 | 170.59% |
| Sep 30, 2022 | 41 | 26 | 173.33% |
| Jun 30, 2022 | 29 | 16 | 123.08% |
| Mar 31, 2022 | 18 | 6 | 50.00% |
| Dec 31, 2021 | 17 | 9 | 112.50% |
| Sep 30, 2021 | 15 | 7 | 87.50% |
| Jun 30, 2021 | 13 | - | - |
| Mar 31, 2021 | 12 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Apellis Pharmaceuticals | 710 |
| Denali Therapeutics | 517 |
| Xenon Pharmaceuticals | 327 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 181 |
| Viridian Therapeutics | 143 |
| Disc Medicine | 142 |
VERA News
- 2 days ago - Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer - GlobeNewsWire
- 26 days ago - Vera Therapeutics, Inc. (VERA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - FDA Fast-Tracks Vera's At-Home Kidney Drug - Benzinga
- 4 weeks ago - Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy - GlobeNewsWire
- 4 weeks ago - Wells Fargo sees short squeeze ahead: here are three stocks to play it - Invezz
- 2 months ago - Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewsWire
- 2 months ago - Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - GlobeNewsWire